Nam Soo Jung, Roh Jong-Lyel, Cho Kyung-Ja, Choi Seung-Ho, Nam Soon Yuhl, Kim Sang Yoon
Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Ann Surg Oncol. 2016 Dec;23(13):4376-4383. doi: 10.1245/s10434-016-5356-3. Epub 2016 Jun 23.
Salivary gland cancer (SGC) is rare and has various pathologies and metastatic potentials. Because distant metastasis can be observed after treatment, as well as at initial presentation, this study aimed to investigate the rates, risk factors, and survivals associated with distant metastasis in patients with SGC.
This study involved 454 consecutive patients with previously untreated SGC who were treated at our tertiary referral center. Clinical factors, operative and pathologic findings, and treatment outcomes were carefully reviewed. Univariate and multivariate analyses were performed to identify factors associated with distant metastasis and their associations with distant metastasis-free survival (DMFS), cancer-specific survival (CSS), and overall survival (OS).
Of 454 patients, 95 (20.9 %) presented with distant metastases; of these, 7 (7.4 %) were at the initial stage, while 88 (92.6 %) were detected during a median follow-up of 100 months (range 24-282). Distant metastases to single and multiple organs were found in 64 (67.4 %) and 31 (32.6 %) patients, respectively, with the most common site being the lung (77.9 %). In multivariate analysis, a non-parotid tumor site, high histological grade, perineural invasion, and T3-4 and N2-3 classifications were independent variables of DMFS, while distant metastasis was an independent variable of CSS and OS (p < 0.005 each). The median survival duration after distant metastasis development was 15 months (range 2-103).
Distant metastasis frequently develops after treatment for SGC and is associated with poor survival outcomes; thus, close surveillance may be required for patients with SGC and risk factors.
涎腺癌(SGC)较为罕见,具有多种病理类型和转移潜能。由于在治疗后以及初次就诊时均可观察到远处转移,本研究旨在调查SGC患者远处转移的发生率、危险因素及生存率。
本研究纳入了在我们三级转诊中心接受治疗的454例未经治疗的连续性SGC患者。仔细回顾了临床因素、手术及病理结果以及治疗结局。进行单因素和多因素分析以确定与远处转移相关的因素及其与无远处转移生存期(DMFS)、癌症特异性生存期(CSS)和总生存期(OS)的关联。
454例患者中,95例(20.9%)出现远处转移;其中,7例(7.4%)为初始阶段出现,而88例(92.6%)是在中位随访100个月(范围24 - 282个月)期间检测到的。分别有64例(67.4%)和31例(32.6%)患者发生单个器官和多个器官的远处转移,最常见的部位是肺(77.9%)。在多因素分析中,非腮腺肿瘤部位、高组织学分级、神经周围侵犯以及T3 - 4和N2 - 3分类是DMFS的独立变量,而远处转移是CSS和OS的独立变量(各p < 0.005)。远处转移发生后的中位生存时间为15个月(范围2 - 103个月)。
SGC治疗后远处转移经常发生,且与生存结局较差相关;因此,对于有SGC及危险因素的患者可能需要密切监测。